BRPI0811486A2 - Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2 - Google Patents
Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2Info
- Publication number
- BRPI0811486A2 BRPI0811486A2 BRPI0811486-2A2A BRPI0811486A BRPI0811486A2 BR PI0811486 A2 BRPI0811486 A2 BR PI0811486A2 BR PI0811486 A BRPI0811486 A BR PI0811486A BR PI0811486 A2 BRPI0811486 A2 BR PI0811486A2
- Authority
- BR
- Brazil
- Prior art keywords
- spla2
- dislipidemia
- inhibitors
- cardiovascular disease
- combination therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91591007P | 2007-05-03 | 2007-05-03 | |
US96959107P | 2007-08-31 | 2007-08-31 | |
US87486907A | 2007-10-18 | 2007-10-18 | |
PCT/US2008/062577 WO2008137803A1 (en) | 2007-05-03 | 2008-05-02 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0811486A2 true BRPI0811486A2 (pt) | 2014-09-30 |
Family
ID=39943969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0811486-2A2A BRPI0811486A2 (pt) | 2007-05-03 | 2008-05-02 | Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2154958A4 (pt) |
JP (1) | JP2010526152A (pt) |
CN (1) | CN101742907A (pt) |
AU (1) | AU2008247451A1 (pt) |
BR (1) | BRPI0811486A2 (pt) |
CA (1) | CA2686157A1 (pt) |
EA (1) | EA200971020A1 (pt) |
WO (1) | WO2008137803A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010081022A1 (en) * | 2009-01-08 | 2010-07-15 | Anthera Pharmaceuticals, Inc. | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia |
RU2483707C1 (ru) * | 2012-05-04 | 2013-06-10 | Лира Талгатовна Гильмутдинова | Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн |
CN115040508A (zh) * | 2022-07-28 | 2022-09-13 | 上海市同仁医院 | 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
PL344571A1 (en) * | 1998-05-01 | 2001-11-05 | Lilly Co Eli | Spla2 |
AU2001236440A1 (en) * | 2000-01-25 | 2001-08-07 | Eli Lilly And Company | Method for the treatment of inflammation with spla2 inhibitors |
US7253194B2 (en) * | 2000-07-24 | 2007-08-07 | The University Of Queensland | Compounds and inhibitors of phospholipases |
TWI314457B (pt) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
WO2006034435A2 (en) * | 2004-09-21 | 2006-03-30 | Point Therapeutics, Inc. | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions |
MX2008005666A (es) * | 2005-11-03 | 2009-03-02 | Ilypsa Inc | Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2. |
-
2008
- 2008-05-02 EA EA200971020A patent/EA200971020A1/ru unknown
- 2008-05-02 WO PCT/US2008/062577 patent/WO2008137803A1/en active Application Filing
- 2008-05-02 CA CA002686157A patent/CA2686157A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811486-2A2A patent/BRPI0811486A2/pt not_active IP Right Cessation
- 2008-05-02 CN CN200880023061A patent/CN101742907A/zh active Pending
- 2008-05-02 JP JP2010507578A patent/JP2010526152A/ja active Pending
- 2008-05-02 EP EP08747605A patent/EP2154958A4/en not_active Withdrawn
- 2008-05-02 AU AU2008247451A patent/AU2008247451A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2154958A1 (en) | 2010-02-24 |
JP2010526152A (ja) | 2010-07-29 |
EA200971020A1 (ru) | 2010-10-29 |
AU2008247451A1 (en) | 2008-11-13 |
CN101742907A (zh) | 2010-06-16 |
CA2686157A1 (en) | 2008-11-13 |
WO2008137803A1 (en) | 2008-11-13 |
EP2154958A4 (en) | 2011-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2019044I2 (el) | Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp) | |
CY2019009I2 (el) | Αναστολεις πρωτεϊνικων κινασων | |
CY2017012I1 (el) | Αναστολεις κινασης τυροσινης bruton | |
CY2017016I2 (el) | Αναστολεις πρωτεασωματος | |
DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
HK1152710A1 (en) | Inhibitors of cytosolic phospholipase a2 | |
CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
BRPI0810365A2 (pt) | Inibidores de mlc-1 de indol 7-substituído | |
NO345061B1 (no) | Anvendelse av DPP-IV inhibitorer | |
BRPI1011129A2 (pt) | métodos e compostos inibidores de janus cinase | |
EP2127251A4 (en) | PROPAGATION OF KNOWLEDGE OF CONFLICT | |
BRPI0910668A2 (pt) | inibidores de proteína quinases | |
BRPI0906735A2 (pt) | Terapia de combinação que compreende inibidores de sglt e inibidores de dpp4 | |
DK2379600T3 (da) | Antistoffer mod tissue factor pathway inhibitor | |
BRPI0810086A2 (pt) | inibidores de tirosina quinase de bruton | |
BRPI0715112A2 (pt) | inibidores de undecaprenil pirofosfato sintase | |
BRPI0814797A2 (pt) | Inibidores dna-pk | |
DK2066662T3 (da) | Serinhydrolaseinhibitorer | |
BRPI0911469A2 (pt) | inibidores de gm-csf e il-17 para terapia | |
FI20065834A0 (fi) | Iskulaite | |
BRPI0920681A2 (pt) | inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17 | |
ITFI20070288A1 (it) | Inibitori delle deacetilasi istoniche | |
BRPI0811486A2 (pt) | Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2 | |
BRPI0923192A2 (pt) | tratamento de eventos cardiacos adversos maiores e síndrome coronária aguda empregando-se terapias de combinação de inibidores de fosfolipase a2 secretória (spla2) ou inibidor de spla2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |